Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Strong Trading Volume – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares saw an uptick in trading volume on Friday . Approximately 5,255 shares changed hands during mid-day trading, an increase of 88% from the previous session’s volume of 2,795 shares.The stock last traded at $50.51 and had previously closed at $50.00.

Analyst Upgrades and Downgrades

ZLDPF has been the topic of several research reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Zacks Research cut shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a report on Thursday, August 13th. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

Zealand Pharma A/S Stock Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. The stock has a market cap of $3.61 billion, a P/E ratio of 8.38 and a beta of 0.88. The company’s 50 day moving average price is $46.26 and its 200-day moving average price is $48.85.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.